BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38014511)

  • 1. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
    Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
    Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
    Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
    Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
    Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
    Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
    Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
    Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
    De Togni E; Cole O; Abboud R
    Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
    Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
    Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
    Pusic I; Lee C; Veeraputhiran M; Minor C; DiPersio JF
    Bone Marrow Transplant; 2024 Feb; 59(2):282-284. PubMed ID: 38071272
    [No Abstract]   [Full Text] [Related]  

  • 16. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
    Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
    Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
    [No Abstract]   [Full Text] [Related]  

  • 17. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
    Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
    Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab combined with ruxolitinib in the treatment of children with steroid resistant graft versus host disease after hematopoietic stem cell transplantation: report of 6 cases.
    Chen J; Lu J; Hong X; Lu Q
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 51(4):470-473. PubMed ID: 37202101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.